Arthur Klausner, MBA

Mr. Klausner has more than two decades of experience working with early-stage life sciences companies, most of this time having been spent as a Partner at the venture capital firms Domain Associates and Pappas Ventures. He currently serves as CEO of both Jade Therapeutics and Gem Pharmaceuticals. He has been a Board Member at Santarus (IPO in 2004), X-Ceptor (acquired by Exelixis in 2004), Orexigen (IPO in 2007), CeNeRx BioPharma, Gentis, and Syndax Pharmaceuticals, and a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005), Cerexa (acquired by Forest Laboratories in 2007), and Optherion.